Page 1 of 4, showing 50 records out of 187 total, starting on record 1, ending on 50
| Publication |
Category |
Year |
|
187. Labrie, F., Martel, C., Gauthier, S., Pelletier, G., Sancéau JY. (2010) Effect of toremifene and ospemifene, compared to acolbifene, on estrogen-sensitive parameters in rat and human uterine tissues, Horm Mol Biol Clin Invest, 1: 139-146. |
Breast Cancer |
2010 |
|
186. Li, S., Han, B., Liu, G., Li, S., Ouellet, J., Labrie, F., Pelletier, G. (2010) Immunocytochemical localization of sex steroid hormone receptors in normal human mammary gland. J Histochem Cytochem. 58:509-15. |
Breast Cancer |
2010 |
|
185. Labrie, F., Cusan, L., Gomez, J.L., Côté, I., Bérubé, R., Bélanger, P., Martel, C., Labrie, C. (2009) Effect of One-Week Treatment with Vaginal Estrogen Preparations on Serum Estrogen Levels in Postmenopausal Women. Menopause, 16: 30-36. |
Breast Cancer |
2009 |
|
184. Li, Z., Luu-The, V., Poisson-Paré, D., Ouellet, J., Li, S., Labrie, F., Pelletier, G. (2009) Expression of enzymes involved in synthesis and metabolism of estradiol in human breast as studied by immunocytochemistry and in situ hybridization. Histol Histopathol, 24: 273-282. |
Breast Cancer |
2009 |
|
183. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Balser, J. (2009) Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women, Menopause, 16: 923-931. |
Breast Cancer |
2009 |
|
182. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Martel, C., Balser, J. (2009) Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy, Menopause, 16: 907-922. |
Breast Cancer |
2009 |
|
181. Labrie, F., Archer, D., Bouchard, C., Fortier, M., Cusan, L., Gomez, J.L., Girard, G., Baron, M., Ayotte, N., Moreau, M., Dubé, R., Côté, I., Labrie, C., Lavoie, L., Berger, L., Gilbert, L, Martel, C., Balser, J. (2009) Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration, Menopause, 16: 897-906. |
Breast Cancer |
2009 |
|
180. Labrie, F., Martel, C. (2009) Concurrent hormone and radiation therapy in patients with breast cancer: how does chemotherapy affect treatment? The Lancet - Reflection and Reaction, 10: 444-445 |
Breast Cancer |
2009 |
|
179. Berger, L., El-Alfy, M., Labrie, F. (2008) Effects of intravaginal dehydroepiandrosterone on vaginal histomorphology, sex steroid receptor expression and cell proliferation in the rat. J Steroid Biochem Mol Biol, 109: 67-80. |
Breast Cancer |
2008 |
|
178. Labrie, F. (2008) Combination of Breast Cancer Prevention with Tissue-Targeted Hormone Replacement Therapy, In: Breast Cancer - Prognosis, Treatment, and Prevention, Second Edition, Pasqualini, J.R., ed., pp. 201-252. |
Breast Cancer |
2008 |
|
177. Pelletier, G., Labrie, C., Martel, C., Labrie, F. (2008) Chronic administration of dehydroepiandrosterone (DHEA) to female monkey and rat has no effect on mammary gland histology. J Steroid Biochem Mol Biol, 108: 102-108. |
Breast Cancer |
2008 |
|
176. Labrie, F., Koutsilieris, M. (2008) The 12th International Congress on Hormonal Steroids and Hormones & Cancer. J Steroid Biochem Mol Biol, 108: 179. |
Breast Cancer |
2008 |
|
175. Han, B., Li, S., Song, D., Poisson-Paré, D., Liu, G., Luu-The, V., Ouellet, J., Li, S., Labrie, F., Pelletier, G. (2008) Expression of 17beta-hydroxysteroid dehydrogenase type 2 and type 5 in breast cancer and adjacent non-malignant tissue: a correlation to clinicopathological parameters. J Steroid Biochem Mol Biol, 112: 194-200 |
Breast Cancer |
2008 |
|
174. Akaza, H., Labrie, F., Namiki, M. (2007) [A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation]. Gan To Kagaku Ryoho. Jpn J Cancer Chemotherapy, 34: 657-669. |
Breast Cancer |
2007 |
|
173. Labrie, F. (2007) Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy. Nat Clin Pract Endocrinol Metab, 3: 584-93. |
Breast Cancer |
2007 |
|
172. Liu, H., Zheng, S.F., Bellemare, V., Pelletier, G., Labrie, F., Luu-The, V. (2007) Expression and localization of estrogenic type 12 17 β-hydroxysteroid dehydrogenase in the cynomolgus monkey. BMC Biochem, 8: 2 |
Breast Cancer |
2007 |
|
171. Labrie, F. (2006) Keyrole of endocrinology in the victory against prostate cancer. Bull. Cancer, 93: 949-58. |
Breast Cancer |
2006 |
|
170. Labrie, F. (2006) Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr Relat Cancer, 13: 335-355. |
Breast Cancer |
2006 |
|
169. Liby, K., Rendi, M., Suh, N., Royce, D.B., Risingsong, R., Williams, C.R., Lamph, W., Labrie, F., Krajewsi, S., Xu, X., Kim, H., Brown, P., Sporn, M.B. (2006) The Combination of the Rexinoid, LG100268, and a SERM, either Arzoxifene or Acolbifene, Synergize in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor Negative Model of Breast Cancer. Clin Cancer Res, 12: 5902-5909. |
Breast Cancer |
2006 |
|
168. Luu-The, V., Tremblay, P., Labrie, F. (2006) Characterization of type 12 17β-hydroxysteroid dehydrogenase (17β-HSD12), an isoform of type 3 17β-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Molecular Endocrinology (Baltimore, Md.), 20: 437-43. |
Breast Cancer |
2006 |
|
167. Song, D., Liu, G., Luu-The, V., Zhao, D., Wang, L., Zhang, H., Xueling, G., Li, S., Desy, L., Labrie, F., Pelletier, G. (2006) Expression of aromatase and 17β-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. J Steroid Biochem Mol Biol, 101: 136-44. |
Breast Cancer |
2006 |
|
166. Tchédam Ngatcha, B., Luu-The, V., Labrie, F., Poirier, D. (2005) Androsterone 3β-Ether-3β-Substituted and Androsterone 3β-Substituted derivatives as inhibitors of type 3 17β-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship. J. Med. Chem., 48: 5257-5268. |
Breast Cancer |
2005 |
|
165. Labrie, F., Champagne, P., Labrie, C., Roy, J., Laverdiere, J., Provencher, L., Potvin, M., Drolet, Y., Pollak, M., Panasci, L., L'Espérance, B., Dufresne, J., Latreille, J., Robert, E., Samson, B., Jolivet, J., Yelle, L., Cusan, L., Diamond, P., Candas, B. (2004) Activity and safety of the orally active precursor of EM-652 (Acolbifene) in Tamoxifen-resistant breast cancer. J Clin Oncol, 22: 864-871. |
Breast Cancer |
2004 |
|
164. Dimitrakakis, C., Zhou, J., Wang, J., Belanger, A., Labrie, F., Cheng, C., Powell, D., Bondy, C. (2003) A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause, 10: 292-298. |
Breast Cancer |
2003 |
|
163. Gutman, M., Couillard, C., Labrie, F., Candas, B., Labrie, C. (2003) Effect of treatment sequence with radiotherapy and the antiestrogen EM-800 on the growth of ZR-75-1 Human mammary carcinoma in nude mice. Int J Cancer, 103: 268-276. |
Breast Cancer |
2003 |
|
162. Jensen, J., Kitlen, J., Briand, P., Labrie, F., Lykkesfeldt, A.E. (2003) Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J. Steroid Biochem Mol Biol, 84: 469-78. |
Breast Cancer |
2003 |
|
161. Labrie, F., El Alfy, M., Berger, L., Labrie, C., Martel, C., Bélanger, A., Candas, B., Pelletier, G. (2003) The combination of a novel SERM with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women's health? Endocrinology, 144: 4700-4706. |
Breast Cancer |
2003 |
|
160. Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.-X., Pelletier, G. (2003) Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocrine Reviews, 24 (2): 152-182. |
Breast Cancer |
2003 |
|
159. Roy, J., Couillard, C., Gutman, M., Labrie, F. (2003) A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat, 81: 223-229. |
Breast Cancer |
2003 |
|
158. Labrie, F. (2002) Endocrine-sensitive cancers of the prostate and breast, in: Baster, J., Melmed, S. et New, M., eds: Genetics in Endocrinology, Lippincott-William and Wilkins, pp 607-661. |
Breast Cancer |
2002 |
|
157. Gutman, M., Couillard, S., Roy, J., Labrie, F., Candas, B., Labrie, C. (2002) Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. International Journal of Cancer, 99: 273-278. |
Breast Cancer |
2002 |
|
156. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2002) DHEA replacement therapy as a source of androgens and estrogens at menopause, in: Genazzani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, Florence, Italy, Parthenon Publishing, pp 249-258. |
Breast Cancer |
2002 |
|
155. Labrie, F., Labrie, C., Bélanger, A., Simard, J. (2002) Third and fourth generation SERMs, in: Manni, A. et Verderame, M., eds: Selective Estrogen Receptor Modulators: Research and Clinical Applications, Totowa, NJ, Humana Press Inc., pp 167-187. |
Breast Cancer |
2002 |
|
154. Labrie, F., Luu-The, V., Labrie, C., Simard, J. (2001) DHEA and its transformation into androgens and estrogens in peripheral target tissues: Intracrinology. Neuroendocrinologie, 22: 185-212. |
Breast Cancer |
2001 |
|
153. Pelletier, G., Luu-The, V., El Alfy, M., Li, S., Labrie, F. (2001) Immunoelectron microscopic localization of 3β-hydroxysteroid dehydrogenase and type 5 17β-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J. Mol. Endocrinol., 26: 11-19. |
Breast Cancer |
2001 |
|
152. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Labrie, C. (2001) DHEA replacement therapy as source of androgens and estrogens at menopause, in: Genazani, A.R., Petraglia, F. et Artini, P.G., eds: Advances in Gynecological Endocrinology, London, UK, Parthenon Publishing, pp 249-258. |
Breast Cancer |
2001 |
|
151. Labrie, F., Labrie, C., Bélanger, A., Giguère, V., Simard, J., Mérand, Y., Gauthier, S., Luu-The, V., Candas, B., Martel, C.E.A. (2001) Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities, in: Scolnick, E.M., ed. Advances in Protein Chemistry, San Diego, CA, Academic Press, pp 293-368. |
Breast Cancer |
2001 |
|
150. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Giguère, V., Tremblay, A., Tremblay, G. (2001) EM-652 (SCH 57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 79: 213-225. |
Breast Cancer |
2001 |
|
149. Labrie, F., Simard, A.R., Labrie, C., Bélanger, A. (2001) EM-652 (SCH57068) a pure SERM in the mammary gland and endometrium. Référence en Gynécologie Obstétrique, 8: 331-336. |
Breast Cancer |
2001 |
|
148. Pelletier, G., El Alfy, M., Labrie, C., Martel, C., Labrie, F. (2001) Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor alpha and prolactin mRNA expression in intact, ovariectomized and GnRH-treated female rats. Neuroendocrinology, 74: 367-374. |
Breast Cancer |
2001 |
|
147. Sauvé, F., McBroom, L.D.B., Gallant, J., Moraitis, A.N., Labrie, F., Giguère, V. (2001) CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol. Cell. Biol, 21: 343-353. |
Breast Cancer |
2001 |
|
146. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., Bélanger, A. (2000) Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16. |
Breast Cancer |
2000 |
|
145. Sourla, A., Richard, V., Labrie, F., Labrie, C. (2000) Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J. Endocrinol., 166: 455-462. |
Breast Cancer |
2000 |
|
144. Couillard, S., Labrie, C., Gauthier, S., Mérand, Y., Singh, S.M., Candas, B., Labrie, F. (2000) Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int. J. Cancer, 85: 424-429. |
Breast Cancer |
2000 |
|
143. Labrie, C., Labrie, F., Bélanger, A., Simard, J., Luo, S., Martel, C. (2000) EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, in: Coutinho, E.M. et Spinola, P., eds: Current Knowledge in Reproductive Medicine. Proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May 1999, Elsevier Science B.V., pp 381-397. |
Breast Cancer |
2000 |
|
142. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Luu-The, V., Candas, B. (2000) Mechanisms of action of estrogens and antiestrogens, in: Aso, T., Yanaihara, T. et Fujimoto, S., eds: The Menopause at the Millenium: Proceedings of the 9th World Congress on the Menopause, October 17-21, 1999, Yokohama, Japan, Parthenon Publishing, pp 14-22. |
Breast Cancer |
2000 |
|
141. Martel, C., Picard, S., Richard, V., Bélanger, A., Labrie, C., Labrie, F. (2000) Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J. Steroid Biochem. Mol. Biol., 74: 45-56. |
Breast Cancer |
2000 |
|
140. Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Labrie, C., Bélanger, A., Labrie, F., Richard, D. (2000) Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int. J. Obes. Relat. Metab. Disord., 24: 830-840. |
Breast Cancer |
2000 |
|
139. The BRCA1 Exon 13 Duplication Screening Group. (2000) The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. Am J Hum Genet., 67: 207-212. |
Breast Cancer |
2000 |
|
138. Boivin, R.P., Poirier, D., Labrie, F. (1999) 17alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids, 64: 825-833. |
Breast Cancer |
1999 |